about
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerChemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial dataRandomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.Maintenance therapy in NSCLC: why? To whom? Which agent?Targeted therapies in small cell lung cancer: a reviewRole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyBase excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancerAfatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?New anti-emetic treatments.ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.Predictive models in palliative care.Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.Across the universe of K-RAS mutations in non-small-cell-lung cancer.Targeting the MET gene for the treatment of non-small-cell lung cancer.Targeted therapy-induced diarrhea: A review of the literature.Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?Thymoma and thymic carcinomas.Diagnosis and management of typical and atypical lung carcinoids.Treatment of lung large cell neuroendocrine carcinoma.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugsOutcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.New findings on thymic epithelial tumors: Something is changing.G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
P50
Q28072004-73C55A35-9F8C-4F9B-BC27-C6531CD67CE1Q29620902-9EE93236-D3F6-46AC-A9B0-901F1DE21C18Q30940337-81B53E9A-F6BE-4204-84AF-C9A01BBF90F8Q34663620-09FB1ADC-E948-4F18-BB8C-328D1BE5B1DAQ35041521-553FB367-6ED1-482B-9441-7941190A2CB3Q35076234-4EF11CE5-DD88-4983-921F-2B9A253576F3Q36287562-1BB26A39-700A-4676-973A-C2EC6E258DC3Q36545375-6EA26EE7-D77C-4FDD-BBAC-EA96C0D1ADD9Q36557507-939BEE97-8F90-4F6F-8A13-03D413DD91E5Q36574080-F3B73E37-B091-4010-A5A0-0546271929BEQ36594244-592E3CE2-DD4B-45EE-B1EF-64576017213AQ36882027-46908825-3561-467A-BA57-12BD3AAAB38CQ37209474-E9F716AE-E6D3-4E70-B10D-DAAF3F97F99CQ37526767-0EFB20DB-24B8-4FEF-B699-8ABB32086D66Q37699578-AC762ACC-3F3C-41DD-9B1E-184856FD6AFFQ37819140-9A60040B-9675-453D-A359-143B5E766227Q38121308-986DF255-9E1B-4EC7-878C-B55023DFE12DQ38151305-1A27BB23-40C7-45A9-9984-1D7CB7B8F034Q38153826-CEB15B61-675F-49BC-AA8D-5ECF151823D3Q38172700-B481002C-5BD7-45E7-92AA-3FD7B62EA3C1Q38174378-CB645ADC-A0E3-4A99-9636-9E974D9B753FQ38269843-8E9260E5-F450-4263-B9E7-CFC1147AAD84Q38293725-E5788396-EA31-40BD-BF4A-FF02F752FF41Q38382493-079BD29A-C4AB-4901-B906-2802D3523952Q38611252-2EE5C38E-A2EF-4B7E-877D-CD557010E8CDQ38714111-07DE4DD3-9B52-4B29-A805-4B6C6BF292F7Q38751034-04F4877B-38F0-43E0-B2F7-987E8672D3BCQ38760870-FF2BE77C-FBE4-4C04-9475-D1E069FB28FCQ38763111-EA0B0D4C-F56B-4028-8D09-E0561EB8011EQ38823755-ED6296FE-C579-4D66-8817-0C0AD1312191Q38854565-10FF57EA-50B5-4B44-9582-E141C4588F11Q38909078-A498023F-5084-4755-9CEA-432FD1B84346Q38916160-1B5DB83D-3C11-4807-A7B2-84EB1D81E54CQ39102558-855D4559-3735-4D31-9D0B-B35A52BDFD3EQ39827211-33928E3E-5505-4184-9621-66B88DF9471BQ40430354-3AF7BF40-1A26-4BBA-AAFF-DF5A4A5FF16DQ40810940-A00B89A3-284F-43F4-856F-9014470A6DDAQ40812047-CC376F58-71FE-452A-B0B1-38373E0CF868Q41442485-08E45EAB-2799-4A42-84D2-0BAE6E518570Q41548711-63A6CF78-8AFC-4940-9963-29A1D68EF154
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marina Garassino
@ast
Marina Garassino
@en
Marina Garassino
@es
Marina Garassino
@nl
type
label
Marina Garassino
@ast
Marina Garassino
@en
Marina Garassino
@es
Marina Garassino
@nl
prefLabel
Marina Garassino
@ast
Marina Garassino
@en
Marina Garassino
@es
Marina Garassino
@nl
P106
P1153
16232960200
P21
P31
P496
0000-0002-3821-5598